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INTRODUCTION
Immunoglobulin A nephropathy (IgAN) is the most com-
mon of all primary glomerulonephritis in developed coun-
tries. It varies largely in geographical distribution, as it is
more frequent in the Asian population (45 cases per million)
than in Caucasians (31 cases per million) (Schena and
Nistor, 2018). In some autopsy and biopsy studies, IgAN
can be found in about 1.5% of the normal population
(Suzuki et al., 2003). It is a mesangioproliferative
glomerulonephritis with characteristic diffuse IgA deposits
in the mesangium. It was first described in 1968 by Jean
Berger and Nicole Hinglais, when immunofluorescence was
introduced in the examination of kidney biopsy material.
Earlier it was called benign disease with recurrent
haematuria, but now it is known that in 40% cases IgAN
leads to end-stage renal disease (ESRD) (Feehally et
al. 2018).
IgAN is diagnosed using immunofluorescence (IF), which
for Latvian patients has been routinely and reliably avail-
able only since 2013, after the Nephrology Centre in Pauls
Stradiòð Clinical University Hospital (PSCUH) started tight
cooperation with the National Centre of Pathology in
Vilnius, Lithuania.
It has been 50 years since the discovery of IgAN, but there
are still many unanswered questions. IgAN has different
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Immunoglobulin A nephropathy (IgAN) is the most common chronic glomerulopathy with variable
clinical manifestations. IgAN diagnostics became possible in Latvia in 2013. The study aim was to
describe IgAN manifestations in the Latvian population by analysing epidemiological, clinical, his-
tological data, and reveal factors that might determine the course of the disease. The retrospec-
tive, one-centre study included biopsy-proven IgAN patients over a five-year period in the
Nephrology Centre at Pauls Stradiòð Clinical University Hospital. Data from inpatient and outpa-
tient medical records were collected. The study included 69 patients with histologically confirmed
IgAN (23% of all renal biopsies): 52% men with mean age of 37. More than a half of them had hy-
pertension, changes in urinalysis and kidney structure, and GFR < ml/min before the biopsy. Pa-
thology data stratified by MEST-C score were: M1 (93%), E1 (5%), S1 (81%), T1 and T2 (24%),
C1 (18%). 20% started renal replacement therapy (RRT). Proteinuria, obesity, hyperuricemia,
high total MEST-C score, and low serum C3 were associated with a worse prognosis. As a signifi-
cant part of patients start RRT in the five-year period after the biopsy, the disease course is not
benign. IgAN in the study population was diagnosed with clinical and histological signs of ad-
vanced disease.
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pathogenic mechanisms and prognostic factors in different
geographic regions. The study of IgAN pathogenesis, clini-
cal, histological, and genetic prognostic markers and treat-
ment continues worldwide. Clinically IgAN can be mani-
fested from asymptomatic changes in urinalysis to rapidly
progressive glomerulonephritis. It is very important to diag-
nose IgAN, evaluate factors that determine renal prognosis
and start timely treatment that can slow or prevent progres-
sion to ESRD, which affects quality of life, ability to work
and life expectancy, as well as health care costs.
Considering different and sometimes even conflicting world
research data, the goal of this study was to uncover the
manifestations of IgAN in our population. The aim of this
study was to analyse epidemiological, clinical, and histo-
logical data of IgAN patients and to discover factors that
might determine the course and prognosis of the disease.
MATERIALS AND METHODS
The study was retrospective and involved a single centre.
Patients at least 18 years old with morphologically con-
firmed IgAN by the presence of IgA deposits shown by
immunofluorescence microscopy at the Nephrology Centre
of Pauls Stradiòð Clinical University Hospital in the period
from January 2013 to December 2017 were included. The
decision to perform the biopsy as well as treatment manage-
ment were determined by the treating physician based on
the following specific indications: impaired kidney function
or changes in urinalysis. The inpatient and outpatient medi-
cal records included the following data: demographic char-
acteristics, comorbidities, previous and current treatment,
history of hypertension and abnormal urinalysis, time of the
dialysis or transplantation after the biopsy, ultrasound and
laboratory results (urinalysis, estimated glomerular filtration
rate (eGFR) using CKD-EPI formula, complement frac-
tions, and other immunology markers), histological data and
serum creatinine available until January 2018. The Oxford
classification was used for biopsy evaluation. It was first
published in 2009, then confirmed and supplemented with
subsequent cohorts, and is used to predict clinical outcome
by MEST-C scoring: mesangial hypercellularity (M),
endocapillary cellularity (E), segmental sclerosis (S), inter-
stitial fibrosis/tubular atrophy (T) and crescents (C)
(Trimarchi et al., 2017). The collected data were analysed
using IBM SPSS Statistics 20. To compare groups, we used
non-parametrical tests (Mann–Whitney, Kruskal–Wallis and
Crosstabs), for correlations — Spearman correlation coeffi-
cient, and for renal survival – the Kaplan-Meier estimator.
The present study was approved by the PSCUH Ethics
Committee (approval nr. 100118-10L; January 10, 2018).
RESULTS
In total, 303 renal biopsies were performed in the Nephro-
logy Centre at Pauls Stradiòð Clinical University Hospital
from 2013 to 2017; 23% of the patients (n = 69) had IgAN
diagnosis. Mean age was 37 (31–46) years and 52% (n =
36) of the sample group were men. Mean BMI was 25.8
(22.8–29.7) kg/m2 (n = 59). Furthermore, 55% (n = 38) of
patients had no previous comorbidities. The remaining pa-
tients had other diseases like gastrointestinal pathologies,
infections (hepatitis B or C, HIV, urinary tract infections,
recurrent tonsillitis), bronchial asthma, epilepsy, diabetes,
psoriasis, celiac disease and thyroiditis. At the time of bi-
opsy 97% (n = 67) of patients had proteinuria, and average
daytime proteinuria was 1.3 (0.6–3.7) g/day (n = 46) (Table
1).
Before the biopsy, 74% (n = 51) of patients had known hy-
pertension on average for three (1–7) years. Moreover, 67%
(n = 46) patients were taking antihypertensive medication
before the biopsy, 58% (n = 40) received angiotensin-con-
verting enzyme inhibitors, and 39% (n = 27) were taking
two or more medications to control blood pressure. Of all
the patients, 71% (n = 49) had known changes in urinalysis
on average for 24 (5–72) months. Ultrasound showed that
41% (22 of 53) of patients had signs of chronic kidney dam-
age at the time of biopsy.
On average, there were 14 (9–21) glomeruli in kidney bi-
opsy reports, and 17% (n = 12) contained less than eight
glomeruli, which is considered insufficient to use Oxford
classification. Histological examination showed that 20%
(n = 4) of biopsies had more than half of glomeruli globally
sclerosed, and segmental glomerulosclerosis were present in




No comorbidities 38 (55)
Proteinuria 67 (97)
24h proteinuria 46 (67)
< 0.5 g/24h 8 (17.5)
0.5–1 g/24h 8 (17.5)
1–3 g/24h 16 (35)
> 3 g/24h 14 (30)
Clinical manifestation
nephritic syndrome 48 (70)
nephrotic proteinuria and haematuria 10 (14)
nephrotic syndrome 1 (1)
asymptomatic urinalysis changes 9 (13)
isolated proteinuria with decreased GFR 1 (1)
GFR at the time of biopsy (ml/min/1.73m
2
)




< 15 5 (7)
Hypertension at the time of biopsy 51 (74)
antihypertensive drugs 46 (67)
ACE inhibitors or ARBs before the biopsy 40 (58)
ACE inhibitors or ARBs after the biopsy 51 (74)
two or more antihypertensive drugs 27 (39)
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81% (n = 46) of biopsies. Light microscopy showed
mesangial hypercellularity and an increase in mesangial ma-
trix was frequently seen (93%); endocapillary infiltration
was less common (5%). Mesangial Glomerular deposits
were observed under immunofluorescence; MEST-C scores
in patients with more than eight glomeruli in biopsies (n =
57) are shown in Table 2. IgA mesangial deposits are the
characteristic and defining feature of the disease; neverthe-
less, IgA deposits were accompanied by IgM deposits in
62.3% of cases, and IgG deposits in 8.7%.
Immunosuppression was received by 17% (n = 12) of pa-
tients, mostly after diagnosis histological confirmation. The
indications for it were nephrotic range proteinuria and rapid
decline of renal function. Only one patient received
immunosuppression three years prior to biopsy, but it was
terminated later. Three patients started renal replacement
therapy (RRT) and one died. There was no unified treat-
ment protocol; patients received different treatment agents:
glucocorticoids in combination with cyclophosphamide (n =
6), glucocorticoids in monotherapy (n = 4), and gluco-
corticoids in combination with cyclosporine and then
changed to mycophenolate mofetil (MMF) (n = 1).
During the follow-up period, 20% (n = 14) patients had de-
cline in eGFR and developed ESRD, and RRT was started
on average 11 months after the biopsy was performed.
Three patients were dialysis dependent at the time of bi-
opsy. In the next years after the biopsy, 9% of patients (n =
6) received a kidney transplant. Unfortunately, 43% (n =
30) of patients had no available data about their kidney
function after the biopsy. Analysis of available follow-up
showed that data kidney function in most cases continued to
decline in the following years after the biopsy (Table 3).
We found statistically significant correlations (p < 0.05),
despite the rather small study group: 1) higher BMI was as-
sociated with higher serum C3 and less glomeruli in biopsy,
2) longer history of hypertension before the biopsy was as-
sociated with longer time until RRT, 3) more globally
sclerosed glomeruli in biopsy were associated with lower
eGFR and shorter time until RRT, 4) more crescents in bi-
opsy were associated with a higher serum complement C4
fraction, 5) creatinine elevation in the 1st year after the bi-
opsy was associated with younger age and more severe
proteinuria, and 6) creatinine elevation in the third to fifth
year after the biopsy was associated with lower serum com-
plement C3 fraction.
Comparing different groups, we found that creatinine was
higher in males, patients with hyperuricemia and higher T
score; proteinuria was more severe in patients with glomer-
ular C3 deposits and serum C4 was higher in patients with
crescents in biopsy (Table 4). More severe 24-hour
proteinuria was more common in adipose patients (BMI >
25 kg/m2), comparing to patients with normal BMI (p =
0.007).
Analysis of renal survival in the group of patients who re-
ceived RRT showed that hyperuricemia as well as T and E
lesions in Oxford classification were associated with worse
renal survival (Fig. 1).
DISCUSSION
This is the first study that shows Latvian data about IgAN
epidemiology, clinical manifestation, and prognosis. In our
population, IgAN was observed in 23% of all biopsies,
which is similar to other European data (Fiorentino et al.,
2016) and corresponds to 0.003% of the Latvian population.
There was no significant difference between genders and
the mean age of diagnosis: 31–46 years. Literature shows
that IgAN usually manifests in the 2nd and 3rd decades
(James et al., 2002), which might indicate later diagnosis in
our population. Nephritic syndrome was the most common















Table 3. Changes in creatinine level after kidney biopsy
Changes of creatinine 1st year,
n = 19
2nd – 3rd year,
n = 12
3rd – 5th year,
n = 6
Elevated < 50% 9 4 2
Elevated = 50% 2 3 3
No significant change 4 3 1
Lowered 4 2 0
Table 4. Observed differences between mean values of creatin, proteinuria,
age and serum C4 in the study group.
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clinical presentation and only 13% of patients had asymp-
tomatic changes in urinalysis, compared to 30–40% re-
ported elsewhere (Trimarchi et al., 2017). It can be thus as-
sumed that these patients in our population were not
diagnosed or were not referred for renal biopsy.
The majority of the patients had a history of hypertension
and abnormal urinalysis until the biopsy, which might indi-
cate that the length of the disease might be 2–3 years on av-
erage. Upon the time of biopsy, 58% of patients had eGFR
less than 60 ml/min/1.73m2 and 7% – ESRD, which indi-
cated far advanced disease and worse renal prognosis. The
same conclusions can be made from histological data, as
81% had segmental glomerulosclerosis and 24% had tubular
atrophy and/or interstitial fibrosis.
Most often, the seen glomerular deposits were IgM (62% of
biopsies), which in some studies were associated with scle-
rotic lesions (Arijana et al., 2017). In the literature, only
less than 5% IgAN patients developed acute kidney failure
with crescentic lesions (Feehally et al., 2018), while in our
study, 18% has crescents, which can be explained by a large
amount of undiagnosed patients with better prognosis.
Treatment was usually conservative, with only 17% receiv-
ing immunosuppressant drugs in different regimens, mostly
in severe proteinuria or with progressive decline of renal
function, leading to different outcomes. However, this
group was too small to make any conclusions.
In literature data, 1/4 (e.g., Steddon et al., 2014) and in our
study 1/5 of IgAN patients, progressed to ESRD and started
RRT on average one year after the biopsy. Most of the pa-
tients who did not progress to ESRD had a tendency of de-
clining renal function in the following years after the bi-
opsy. This group also was too small to conduct more
analysis and draw conclusions.
Some of the study results seem to be well known, for exam-
ple, the association between sclerosed glomeruli and eGFR,
but others are new findings that require future investigation.
Considering the results, lower serum C3 and higher serum
C4 were associated with worsening kidney function. Fur-
thermore, more crescents were associated with higher serum
C4, which was also found in a study in China (Pan et al.,
2017). Evidence suggests that IgAN is associated with an
increase in the activation of the mannose-binding lectin
(MBL) pathway, measured as C4d and MBL deposition in
glomerulus, so the increase in serum levels of MBL is asso-
ciated with higher levels of serum complement C4.
Higher BMI is associated with more severe proteinuria
linked to glomerular hyperfiltration, as well as a higher
level of hyperuricaemia, and serum C3. Many reports have
shown that there is a strong relationship between C3 and
acylation-stimulating protein (C3a-desArg) levels, adipose
tissue, and risk factors for cardiovascular disease, metabolic
syndrome and diabetes. The C3 fragment, C3a-desArg,
functions as a hormone that has insulin-like effects and fa-
cilitates triglyceride metabolism. Adipose tissue produces
and regulates the levels of complement components, which
promotes generation of inflammatory initiators such as the
anaphylatoxins C3a and C5a. The anaphylatoxins trigger a
cyto/chemokine response in proportion to the amount of ad-
ipose tissue present, and induce inflammation (Barbu et al.,
2015).
The disadvantages of our study were a small amount of
IgAN patients, small group sizes, short retrospective obser-
Fig. 1. Analysis of renal survival and a) hyperuricemia; b) tubular atrophy
and interstitial fibrosis, and c) endocapillary hypercellularity in renal bi-
opsy material of patients who started renal replacement therapy in the
five-year period after renal biopsy.
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vational follow-up period, and some unavailable data. How-
ever, for the first time our study presents the epidemiologic
situation and manifestation of the most common type of
glomerulonephritis in the Latvian population, since precise
diagnostics of this disease became available only in 2013
due to successful international collaboration.
There are also some research ideas for the future. As IgAN
is not a so benign disease, it would be useful to identify im-
munologic or genetic criteria that worsen prognosis, in or-
der to focus on body weight reduction for the patients with
changes in urinalysis or decreased kidney function.
In conclusion, a significant part of patients begin renal re-
placement therapy in the five-year period after the biopsy,
and the disease is not so benign. Proteinuria, adiposity,
hyperuricaemia, higher MEST-C score in histological ex-
amination, lower complement C3, and signs of chronic kid-
ney disease at the time of diagnosis are markers of worse
IgAN prognosis. IgAN in the Latvian population is diag-
nosed with clinical and histological signs of advanced dis-
ease.
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IMÛNOGLOBULÎNA A NEFROPÂTIJAS EPIDEMIOLOÌISKAIS UN KLÎNISKI MORFOLOÌISKAIS RAKSTUROJUMS LATVIJÂ
Imûnglobulîna A nefropâtija (IgAN) ir visizplatîtâkais hroniskais glomerulonefrîts ar daþâdâm klîniskâm izpausmçm. Ðî pçtîjuma mçríis
bija atklât IgAN izpausmes Latvijas populâcijâ, analizçjot epidemioloìiskos, klîniskos, histoloìiskos datus, un atklât faktorus, kas varçtu
ietekmçt slimîbas gaitu. Tas ir retrospektîvs, viena centra pçtîjums. Tika iekïauti IgAN pacienti, kuriem mûsu centrâ — Paula Stradiòa
Klîniskâs universitâtes slimnîcas Nefroloìijas centrâ piecu gadu laikâ tika diagnosticçta IgAN pçc veiktâs nieru biopsijas. Tika apkopoti
dati no stacionâra un ambulatoriem medicîniskajiem ierakstiem. Pçtîjumâ piedalîjâs 69 pacienti ar histoloìiski apstiprinâtu IgAN (23% no
visâm nieru biopsijâm), 52% vîrieði, vidçjais vecums 37 gadi. Vairâk kâ pusei no viòiem bija hipertensija, izmaiòas urîna analîzç un
hroniskas izmaiòas nieru struktûrâ, GFR < ml/min pirms biopsijas. Histoloìijas dati, kas stratificçti pçc MEST-C klasifikâcijas, bija: M1
(93%), E1 (5%), S1 (81%), T1 un T2 (24%), C1 (18%). 17% saòçma imûnsupresîvu ârstçðanu ar atðíirîgiem rezultâtiem, 20% uzsâka nieru
aizstâjterapiju (NAT). Proteînûrija, aptaukoðanâs, hiperurikçmija, augsts kopçjais MEST-C râdîtâjs, zems C3 lîmenis serumâ bija saistîts ar
sliktâku prognozi. Tâ kâ ievçrojama daïa pacientu uzsâka NAT piecu gadu laikâ pçc biopsijas, slimîbas gaita nav labdabîga. IgAN Latvijas
iedzîvotâjiem tiek diagnosticçta ar progresçjoðas slimîbas klîniskajâm un histoloìiskajâm pazîmçm.
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